Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Attention-Deficit/Hyperactivity Disorder (ADHD)

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Trial Timeline

Feb 1, 2016 → Jul 25, 2016

NCT ID

NCT02633527

About Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812

Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812 is a phase 2 stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT02633527. Target conditions include Attention-Deficit/Hyperactivity Disorder (ADHD).

What happened to similar drugs?

8 of 11 similar drugs in Attention-Deficit/Hyperactivity Disorder (ADHD) were approved

Approved (8) Terminated (0) Active (3)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅SPN-812Supernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02633527	Phase 2	Completed	Feb 1, 2016	Jul 25, 2016	Attention-Deficit/Hyperactivity Disorder (ADHD)

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder (ADHD)

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
ABT-089 + atomoxetine + placebo	AbbVie	Phase 2	35
ABT-089 + Placebo	AbbVie	Phase 2	35
ABT-089	AbbVie	Phase 2	35
ABT-089 + placebo	AbbVie	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
SPN-812	Supernus Pharmaceuticals	Approved	37
IR Viloxazine + Placebo	Supernus Pharmaceuticals	Phase 1/2	26
SPN-812	Supernus Pharmaceuticals	Approved	37
100mg SPN-812 + Placebo	Supernus Pharmaceuticals	Approved	44
SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + SPN-812	Supernus Pharmaceuticals	Phase 3	34
SPN-812	Supernus Pharmaceuticals	Phase 3	38
TD-9855 + TD-9855 + Placebo	Theravance Biopharma	Phase 2	29